Skip to main content
. 2019 May 31;16:e00060. doi: 10.1016/j.fawpar.2019.e00060

Fig. 3.

Fig. 3

Levels of antibodies against EgHF, Em2 and Em18 at initial diagnosis and 1st follow-up in immunocompetent (ICT) and immunocompromised (ICR) patients. Horizontal bars represent the median. The figure shows a significant decrease of the antibody levels against all 3 antigens after treatment for ICR and for ICT patients (Fig. 3, p ≤ 0.001, Wilcoxon sign-ranktest).